Kevin J. Mcnamara Sells 1,500 Shares of Chemed Co. (NYSE:CHE) Stock

Chemed Co. (NYSE:CHEGet Free Report) CEO Kevin J. Mcnamara sold 1,500 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $544.17, for a total transaction of $816,255.00. Following the completion of the sale, the chief executive officer now owns 107,049 shares in the company, valued at $58,252,854.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Chemed Stock Performance

Shares of NYSE CHE opened at $543.66 on Friday. Chemed Co. has a fifty-two week low of $492.84 and a fifty-two week high of $654.62. The company has a market cap of $8.23 billion, a price-to-earnings ratio of 29.26, a PEG ratio of 2.22 and a beta of 0.46. The business’s 50 day moving average price is $581.59 and its 200-day moving average price is $592.75.

Chemed (NYSE:CHEGet Free Report) last released its earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing the consensus estimate of $5.09 by ($0.41). The business had revenue of $589.23 million for the quarter, compared to the consensus estimate of $587.18 million. Chemed had a return on equity of 30.52% and a net margin of 12.36%. Sell-side analysts predict that Chemed Co. will post 21.72 earnings per share for the current year.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Thursday, May 30th will be paid a $0.40 dividend. The ex-dividend date is Thursday, May 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.29%. Chemed’s dividend payout ratio is currently 8.61%.

Wall Street Analysts Forecast Growth

CHE has been the topic of a number of recent research reports. Royal Bank of Canada decreased their price objective on Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 21st. Oppenheimer increased their price target on Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Finally, upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th.

View Our Latest Research Report on CHE

Hedge Funds Weigh In On Chemed

A number of institutional investors have recently modified their holdings of CHE. DekaBank Deutsche Girozentrale grew its stake in Chemed by 34.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 154,579 shares of the company’s stock worth $98,516,000 after purchasing an additional 39,633 shares in the last quarter. EULAV Asset Management increased its stake in shares of Chemed by 7.5% during the first quarter. EULAV Asset Management now owns 111,399 shares of the company’s stock valued at $71,510,000 after buying an additional 7,800 shares during the period. Cetera Advisors LLC bought a new stake in shares of Chemed in the first quarter valued at about $267,000. Second Line Capital LLC lifted its stake in Chemed by 7.1% in the first quarter. Second Line Capital LLC now owns 3,648 shares of the company’s stock worth $2,342,000 after acquiring an additional 242 shares during the period. Finally, LRI Investments LLC bought a new position in Chemed during the 1st quarter worth about $171,000. 95.85% of the stock is owned by hedge funds and other institutional investors.

About Chemed

(Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Read More

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with's FREE daily email newsletter.